BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells()

Among different cancer immunotherapy approaches, bispecific antibodies (BsAbs) are of great interest due to their ability to recruit immune cells to kill tumor cells directly. Various BsAbs against Her2 tumor cells have been proposed with potent cytotoxic activities. However, most of these formats r...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Jieyu, Lin, Limin, Li, Jing, Liu, Jiayu, Zhou, Changhua, Pan, Haitao, Shu, Rui, Dong, Bin, Cao, Donglin, Li, Qing, Wang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548338/
https://www.ncbi.nlm.nih.gov/pubmed/28797938
http://dx.doi.org/10.1016/j.tranon.2017.07.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548338/
https://www.ncbi.nlm.nih.gov/pubmed/28797938
http://dx.doi.org/10.1016/j.tranon.2017.07.003

Ejemplares similares